CCORF Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $171
Buy Rating Affirmed for BioNTech SE on Strong Phase 2 Results and Positive Valuation
H.C. Wainwright Maintains BioNTech(BNTX.US) With Buy Rating, Maintains Target Price $113
Morgan Stanley Maintains BioNTech(BNTX.US) With Hold Rating, Maintains Target Price $101
BioNTech SE (BNTX) Receives a Hold From Morgan Stanley
Morgan Stanley Keeps Their Hold Rating on BioNTech SE (BNTX)
Morgan Stanley Sticks to Their Hold Rating for BioNTech SE (BNTX)
Morgan Stanley Sticks to Its Hold Rating for BioNTech SE (BNTX)
BioNTech Analyst Ratings
BioNTech Analyst Ratings
BioNTech Analyst Ratings
BioNTech Analyst Ratings
BioNTech Analyst Ratings
BioNTech Analyst Ratings
HC Wainwright & Co. Reiterates Buy on BioNTech, Maintains $113 Price Target
Reiterating Buy on BioNTech Amid Strategic Growth and Upcoming Catalysts
Critical Insights From BioNTech Analyst Ratings: What You Need To Know
BioNTech Analyst Ratings
Analysts Conflicted on These Healthcare Names: Nektar Therapeutics (NKTR) and BioNTech SE (BNTX)
Buy Rating on BioNTech SE Amidst Undervaluation and Strong Pipeline Prospects